Leap Therapeutics’ Chairman Buys Nearly 200,000 Shares as Insider Confidence Fuels a 40% Weekly Rally

Insider Activity Highlights a Strategic Shift

Leap Therapeutics’ most recent insider transaction, filed on March 13, 2026, saw Chairman‑and‑Board Member Christopher Mirabelli acquire 74,700 shares of the company’s common stock. The purchase came after a wave of RSU settlements that saw Mirabelli’s holdings swell to 190,376 shares. The move is noteworthy not only because it represents a sizable concentration of equity for a senior executive, but also because it follows a pattern of RSU vesting that has been a feature of Leap’s recent compensation structure.

What This Means for Investors

Leap’s stock has already posted a 39.7 % weekly rally, a 91.3 % YTD gain, and a market cap of roughly $32.9 million, underscoring the market’s enthusiasm for the company’s dual focus on oncology and privacy‑tech. The director’s purchase is therefore a bullish signal that senior management believes the current valuation will continue to rise, particularly as the company looks to advance its Phase‑2 sirexatamab program and expand its digital‑asset platform. The transaction also coincides with a modest 0.13 % rise in share price and a +9 sentiment score on social media, suggesting that the market is already reacting favorably.

Mirabelli’s Transaction Profile

Mirabelli’s insider activity over the past year has been characterized by a mix of large RSU settlements and spot purchases. In December 2025, he sold 2,136 shares and bought 94,050 RSUs, followed by a 22,500 share purchase in March 2025. The March 2026 purchases add to a cumulative holding of nearly 200,000 shares, a significant jump from the 678,456 shares reported in early April 2025. His trading pattern—RSU vesting followed by a concentrated buy—suggests a strategy of locking in equity value before the company’s next funding round or regulatory milestone.

Implications for Leap’s Future

The combined insider activity—Mirabelli’s large holdings, the broader buy‑pressure from other insiders such as Dietz, Oei, and LI, and the company’s positive fundamentals—positions Leap to potentially unlock further upside. Investors should watch for upcoming data from the sirexatamab Phase 2 trial and any announcements regarding the company’s privacy‑tech initiatives, as these developments will likely influence the stock’s trajectory. The current insider confidence, coupled with the company’s strong earnings outlook and growing pipeline, points to a compelling narrative for long‑term growth.